We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

EXPO:NASDAQExponent, Inc. Analysis

Data as of 2026-07-07 - not real-time

$61.18

Latest Price

6/10Risk

Risk Level: Medium

Executive Summary

Exponent, Inc. (EXPO) is trading at $61.18, just below the identified resistance of $61.60 and well under the 200‑day SMA of $67.56, signaling a bearish price context. Technical momentum is mixed: the MACD histogram is positive (+0.57) indicating short‑term bullish pressure, yet the 30‑day volatility is elevated at 31% and the beta of ~0.6 suggests modest market sensitivity. On the fundamentals side, the company posts solid profitability with a 27% operating margin, 19.8% net margin, and a 27.9% ROE, while maintaining a healthy cash position ($118M) and a modest debt‑to‑equity of 24%. The dividend yield of 2% is backed by a payout ratio of 56%, supporting its sustainability.
Valuation metrics raise caution: the trailing P/E of 28.6 is below the industry average of 32.2, yet the DCF‑derived fair value of $31.97 is less than half the current market price, indicating the stock is likely overvalued. With limited upside potential and a bearish trend, the short‑term bias leans toward a defensive stance, while the strong cash flow and dividend make the stock a modest hold for income‑focused investors over medium to long horizons.

Market Outlook

Short Term

< 1 year
Cautious
Model confidence: 7/10

Key Factors

  • price near resistance and below 200‑day SMA
  • high short‑term volatility
  • technical MACD divergence with bearish trend

Medium Term

1–3 years
Neutral
Model confidence: 6/10

Key Factors

  • sustainable 2% dividend yield
  • strong operating and net margins
  • valuation gap between market price and DCF fair value

Long Term

> 3 years
Neutral
Model confidence: 5/10

Key Factors

  • consistent cash generation and low debt load
  • high ROE indicating efficient capital use
  • sector cyclicality and overvaluation limiting upside

Key Metrics & Analysis

Financial Health

Revenue Growth10.50%
Profit Margin19.76%
P/E Ratio28.6
ROE27.94%
ROA10.06%
Debt/Equity23.95
P/B Ratio8.8
Op. Cash Flow$123.5M
Free Cash Flow$73.8M
Industry P/E32.2

Technical Analysis

TrendBearish
RSI59.1
Support$54.07
Resistance$61.60
MA 20$58.19
MA 50$59.64
MA 200$67.56
MACDBullish
VolumeStable
Fear & Greed Index93.63

Valuation

Fair Value$31.97
Target Price$81.67
Upside/Downside33.49%
GradeOvervalued
TypeGrowth
Dividend Yield2.00%

Risk Assessment

Beta0.60
Volatility31.16%
Sector RiskMedium
Reg. RiskMedium
Geo RiskMedium
Currency RiskLow
Liquidity RiskLow

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.